Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis (vol 23, pg 596, 2017)

被引：4
|
作者：
Kalincik, T.
Jokubaitis, V
Spelman, T.
机构：
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷 / 14期
关键词：
D O I：
10.1177/1352458517735739
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
    Alping, Peter
    Askling, Johan
    Burman, Joachim
    Fink, Katharina
    Fogdell-Hahn, Anna
    Gunnarsson, Martin
    Hillert, Jan
    Langer-Gould, Annette
    Lycke, Jan
    Nilsson, Petra
    Salzer, Jonatan
    Svenningsson, Anders
    Vrethem, Magnus
    Olsson, Tomas
    Piehl, Fredrik
    Frisell, Thomas
    ANNALS OF NEUROLOGY, 2020, 87 (05) : 688 - 699
  • [32] Moving to Fingolimod From Natalizumab in Multiple Sclerosis: The ENIGM Is Not Solved
    Bianco, Assunta
    Rossini, Paolo Maria
    Mirabella, Massimiliano
    JAMA NEUROLOGY, 2014, 71 (07) : 924 - 925
  • [33] Fingolimod/natalizumab withdrawalReactivation of multiple sclerosis: 2 case reports
    Reactions Weekly, 2017, 1656 (1) : 221 - 221
  • [34] Multiple Sclerosis in Childhood and Adolescence: Fingolimod versus Interferon beta-1a
    Lorenz, Judith
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2019, 87 (04) : 210 - 210
  • [35] Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab
    Fragoso, Yara Dadalti
    da Gama, Paulo Diniz
    Gomes, Sidney
    Netto Khouri, Jussara Mathias
    da Cunha Matta, Andre Palma
    Mendes, Maria Fernanda
    Aparecida Vieira Stella, Carla Renata
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 6 : 64 - 65
  • [36] Treating multiple sclerosis with fingolimod or intramuscular interferon
    Pozzilli, Carlo
    Prosperini, Luca
    Borriello, Giovanna
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (11) : 1957 - 1960
  • [37] Comparative Effectiveness of Cladribine versus Fingolimod in the Treatment of Highly Active Relapsing Multiple Sclerosis: The MERLYN Study
    Brownlee, W.
    Haghikia, A.
    Hayward, B.
    Waser, N.
    Kayaniyil, S.
    Khan, Z.
    Duncan, J.
    Millar, S.
    Harty, G.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 63 - 63
  • [38] Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies (vol 77, pg 184, 2020)
    Luna, G.
    Alping, P.
    Burman, J.
    JAMA NEUROLOGY, 2021, 78 (11) : 1413 - 1413
  • [39] Imaging outcome measures for progressive multiple sclerosis trials (vol 23, pg 1614, 2017)
    Moccia, M.
    De Stefano, N.
    Barkhof, F.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP32 - NP32
  • [40] Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis
    Nygaard, Gro Owren
    Torgauten, Hilde
    Skattebol, Lars
    Hogestol, Einar August
    Sowa, Piotr
    Myhr, Kjell-Morten
    Torkildsen, Oivind
    Celius, Elisabeth Gulowsen
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 62
12345